Methotrexate Hampers Immunogenicity to BNT162b2 mRNA COVID-19 Vaccine in Immune-Mediated Inflammatory Disease (2021) Haberman R, Herati R, Simon D, Samanovic M, Tuen M, Blank R, Koralov S, et al. Conference contribution Automatic Detection of Bone Marrow Lesions from Knee MRI Data from the OAI Study (2021) Liu S, Sun X, Roemer F, Ashbeck E, Bedrick E, Li ZM, Guermazi A, Kwoh K Conference contribution Humoral and Cellular Immune Responses to SARS–CoV-2 Infection and Vaccination in Autoimmune Disease Patients With B Cell Depletion (2021) Simon D, Tascilar K, Schmidt K, Manger B, Weckwerth L, Sokolova M, Bucci L, et al. Journal article Reply (2020) Soare A, Distler J Journal article, Letter Secukinumab Significantly Decreased Joint Synovitis Measured by Power Doppler Ultrasonography in Biologic-naive Patients with Active Psoriatic Arthritis: Primary (12-Week) Results from a Randomized, Placebo-Controlled Phase III Study (2020) D'Agostino M, Schett G, Lopez-Rdz A, Senolt L, Maldonado-Cocco J, Burgos-Vargas R, Naredo E, et al. Conference contribution Longitudinally Assessed Structural Abnormalities on MRI and Relative Contributions to Risk of Incident Radiographic Knee Osteoarthritis over 10 Years of Follow-up (2020) Kwoh CK, Guermazi A, Ashbeck E, Hu C, Bedrick E, Sharma L, Eaton C, et al. Conference contribution Target Outcomes in Psoriatic Arthritis: Simultaneous Achievement of ACR50-Psoriasis Area and Severity Index 100 and Beyond: Insights from Open-Label, Assessor-Blinded Study at Week 24 (2020) Smolen J, Behrens F, Liu-Leage S, Sapin C, De La Torre I, Meszaros G, Schett G, et al. Conference contribution The Joint Association of Steps/day and Typical Sedentary Bout Length with Worsening Knee Cartilage Damage over Two Years: The MOST Study (2020) Voinier D, Neogi T, Stefanik J, Guermazi A, Roemer F, Master H, Thoma L, et al. Conference contribution Secukinumab Provides Sustained Improvements in Clinical and Imaging Outcomes in Patients with Psoriatic Arthritis and Axial Manifestations: Results from the MAXIMISE Trial (2020) Baraliakos X, Gossec L, Pournara E, Jeka S, Blanco R, D'Angelo S, Schett G, et al. Conference contribution Brain fMRI Predicts Responses to Certolizumab Pegol in RA. an International, Multi-center, Randomized, Double-blind, Placebocontrolled Trial (PreCePRA) (2020) Rech J, Schenker H, Tascilar K, Hagen M, Kleyer A, Simon D, Mendez LV, et al. Conference contribution